Emergent Medical Partners

Type

Venture Capital

Status

Active

Location

San Jose, United States

Total investments

36

Average round size

20M

Portfolio companies

22

Rounds per year

2.00

Lead investments

2

Follow on index

0.39

Exits

9

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
Therapeutic DevicesBiotechnologyOther Healthcare Technology SystemsHealth CareHealth DiagnosticsWellnessMedical DeviceMedicalCloud ComputingTherapeutics

Summary

The fund was located in North America if to be more exact in United States. The leading representative office of defined VC is situated in the Portola Valley.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Emergent Medical Partners, startups are often financed by Split Rock Partners, Asset Management Ventures (AMV), Morgenthaler Ventures. The meaningful sponsors for the fund in investment in the same round are Morgenthaler Ventures, Split Rock Partners, Asset Management Ventures (AMV). In the next rounds fund is usually obtained by Asset Management Ventures (AMV), New Enterprise Associates, Canaan Partners.

Besides them, we counted 2 critical employees of this fund in our database.

Among the various public portfolio startups of the fund, we may underline EBR Systems, Fractyl Laboratories, CytoPherx The fund has no exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. We can highlight the next thriving fund investment areas, such as Robotics, Biopharma. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund.

When the investment is from Emergent Medical Partners the average startup value is 50-100 millions dollars. The real fund results show that this VC is 5 percentage points less often commits exit comparing to other companies. This Emergent Medical Partners works on 4 percentage points more the average amount of lead investments comparing to the other organizations. The top amount of exits for fund were in 2018. The important activity for fund was in 2017. Despite it in 2019 the fund had an activity. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 deals per year.

Show more

Investor highlights

Industry focus
MedtechBiotech/Life Sciences
Stage focus
Series ASeries B

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
36
Lead investments
2
Exits
9
Rounds per year
2.00
Follow on index
0.39
Investments by industry
  • Health Care (33)
  • Medical Device (29)
  • Medical (24)
  • Biotechnology (13)
  • Health Diagnostics (6)
  • Show 14 more
Investments by region
  • United States (35)
Peak activity year
2017
Number of Unicorns
1
Number of Decacorns
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
14
Avg. valuation at time of investment
112M
Group Appearance index
0.97
Avg. company exit year
8
Avg. multiplicator
3.68
Strategy success index
0.50

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Cianna Medical 28 Apr 2011 Health Care, Medical Device, Medical Early Stage Venture 12M United States, California
Shape Memory Medical 04 Mar 2024 Health Care, Medical Device, Therapeutics Late Stage Venture 38M United States, California, San Jose

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.